세계의 PARP(Poly ADP-Ribose Polymerase) 억제제 시장(2025-2029년)

The parp (Poly ADP-Ribose Polymerase) inhibitors market is forecasted to grow by USD 19,535.6 mn during 2024-2029, accelerating at a CAGR of 22.5% during the forecast period. The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expanded application of parp inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's parp (Poly ADP-Ribose Polymerase) inhibitors market is segmented as below:

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By End-user

• Ovarian cancer
• Breast cancer
• Others

By Drug Class

• Olaparib
• Niraparib
• Rucaparib
• Talazoparib
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the extensive ongoing research as one of the prime reasons driving the parp (Poly ADP-Ribose Polymerase) inhibitors market growth during the next few years. Also, growing prevalence of cancer and new research areas in human genes will lead to sizable demand in the market.

The report on the parp (Poly ADP-Ribose Polymerase) inhibitors market covers the following areas:

• PARP (Poly ADP-Ribose Polymerase) Inhibitors Market sizing
• PARP (Poly ADP-Ribose Polymerase) Inhibitors Market forecast
• PARP (Poly ADP-Ribose Polymerase) Inhibitors Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading parp (Poly ADP-Ribose Polymerase) inhibitors market vendors that include AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd.. Also, the parp (Poly ADP-Ribose Polymerase) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market By Geographical Landscape
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
  • Overview on criticality of inputs and factors of differentiation
• 2.3 Factors of disruption
  • Overview on factors of disruption
• 2.4 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

• 3.1 Market ecosystem
  • Parent Market
  • Data Table on - Parent Market
• 3.2 Market characteristics
  • Market characteristics analysis
• 3.3 Value chain analysis
  • Value chain analysis

4 Market Sizing

• 4.1 Market definition
  • Offerings of companies included in the market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029
  • Chart on Global - Market size and forecast 2024-2029 ($ million)
  • Data Table on Global - Market size and forecast 2024-2029 ($ million)
  • Chart on Global Market: Year-over-year growth 2024-2029 (%)
  • Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

• 5.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023
  • Historic Market Size - Data Table on Global PARP (Poly ADP-Ribose Polymerase) Inhibitors Market 2019 - 2023 ($ million)
• 5.2 Distribution Channel segment analysis 2019 - 2023
  • Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
• 5.3 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.4 Drug Class segment analysis 2019 - 2023
  • Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 The impact of AI in the global PARP (poly ADP-ribose polymerase) inhibitors market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition
  • Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Distribution Channel

• 8.1 Market segments
  • Chart on Distribution Channel - Market share 2024-2029 (%)
  • Data Table on Distribution Channel - Market share 2024-2029 (%)
• 8.2 Comparison by Distribution Channel
  • Chart on Comparison by Distribution Channel
  • Data Table on Comparison by Distribution Channel
• 8.3 Retail pharmacies - Market size and forecast 2024-2029
  • Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
• 8.4 Hospital pharmacies - Market size and forecast 2024-2029
  • Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
• 8.5 Online pharmacies - Market size and forecast 2024-2029
  • Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
  • Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
  • Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
• 8.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ million)
  • Data Table on Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
  • Chart on End-user - Market share 2024-2029 (%)
  • Data Table on End-user - Market share 2024-2029 (%)
• 9.2 Comparison by End-user
  • Chart on Comparison by End-user
  • Data Table on Comparison by End-user
• 9.3 Ovarian cancer - Market size and forecast 2024-2029
  • Chart on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
  • Data Table on Ovarian cancer - Market size and forecast 2024-2029 ($ million)
  • Chart on Ovarian cancer - Year-over-year growth 2024-2029 (%)
  • Data Table on Ovarian cancer - Year-over-year growth 2024-2029 (%)
• 9.4 Breast cancer - Market size and forecast 2024-2029
  • Chart on Breast cancer - Market size and forecast 2024-2029 ($ million)
  • Data Table on Breast cancer - Market size and forecast 2024-2029 ($ million)
  • Chart on Breast cancer - Year-over-year growth 2024-2029 (%)
  • Data Table on Breast cancer - Year-over-year growth 2024-2029 (%)
• 9.5 Others - Market size and forecast 2024-2029
  • Chart on Others - Market size and forecast 2024-2029 ($ million)
  • Data Table on Others - Market size and forecast 2024-2029 ($ million)
  • Chart on Others - Year-over-year growth 2024-2029 (%)
  • Data Table on Others - Year-over-year growth 2024-2029 (%)
• 9.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)
  • Data Table on Market opportunity by End-user ($ million)

10 Market Segmentation by Drug Class

• 10.1 Market segments
  • Chart on Drug Class - Market share 2024-2029 (%)
  • Data Table on Drug Class - Market share 2024-2029 (%)
• 10.2 Comparison by Drug Class
  • Chart on Comparison by Drug Class
  • Data Table on Comparison by Drug Class
• 10.3 Olaparib - Market size and forecast 2024-2029
  • Chart on Olaparib - Market size and forecast 2024-2029 ($ million)
  • Data Table on Olaparib - Market size and forecast 2024-2029 ($ million)
  • Chart on Olaparib - Year-over-year growth 2024-2029 (%)
  • Data Table on Olaparib - Year-over-year growth 2024-2029 (%)
• 10.4 Niraparib - Market size and forecast 2024-2029
  • Chart on Niraparib - Market size and forecast 2024-2029 ($ million)
  • Data Table on Niraparib - Market size and forecast 2024-2029 ($ million)
  • Chart on Niraparib - Year-over-year growth 2024-2029 (%)
  • Data Table on Niraparib - Year-over-year growth 2024-2029 (%)
• 10.5 Rucaparib - Market size and forecast 2024-2029
  • Chart on Rucaparib - Market size and forecast 2024-2029 ($ million)
  • Data Table on Rucaparib - Market size and forecast 2024-2029 ($ million)
  • Chart on Rucaparib - Year-over-year growth 2024-2029 (%)
  • Data Table on Rucaparib - Year-over-year growth 2024-2029 (%)
• 10.6 Talazoparib - Market size and forecast 2024-2029
  • Chart on Talazoparib - Market size and forecast 2024-2029 ($ million)
  • Data Table on Talazoparib - Market size and forecast 2024-2029 ($ million)
  • Chart on Talazoparib - Year-over-year growth 2024-2029 (%)
  • Data Table on Talazoparib - Year-over-year growth 2024-2029 (%)
• 10.7 Others - Market size and forecast 2024-2029
  • Chart on Others - Market size and forecast 2024-2029 ($ million)
  • Data Table on Others - Market size and forecast 2024-2029 ($ million)
  • Chart on Others - Year-over-year growth 2024-2029 (%)
  • Data Table on Others - Year-over-year growth 2024-2029 (%)
• 10.8 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ million)
  • Data Table on Market opportunity by Drug Class ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
  • Chart on Market share By Geographical Landscape 2024-2029 (%)
  • Data Table on Market share By Geographical Landscape 2024-2029 (%)
• 12.2 Geographic comparison
  • Chart on Geographic comparison
  • Data Table on Geographic comparison
• 12.3 North America - Market size and forecast 2024-2029
  • Chart on North America - Market size and forecast 2024-2029 ($ million)
  • Data Table on North America - Market size and forecast 2024-2029 ($ million)
  • Chart on North America - Year-over-year growth 2024-2029 (%)
  • Data Table on North America - Year-over-year growth 2024-2029 (%)
• 12.4 Europe - Market size and forecast 2024-2029
  • Chart on Europe - Market size and forecast 2024-2029 ($ million)
  • Data Table on Europe - Market size and forecast 2024-2029 ($ million)
  • Chart on Europe - Year-over-year growth 2024-2029 (%)
  • Data Table on Europe - Year-over-year growth 2024-2029 (%)
• 12.5 Asia - Market size and forecast 2024-2029
  • Chart on Asia - Market size and forecast 2024-2029 ($ million)
  • Data Table on Asia - Market size and forecast 2024-2029 ($ million)
  • Chart on Asia - Year-over-year growth 2024-2029 (%)
  • Data Table on Asia - Year-over-year growth 2024-2029 (%)
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
  • Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
  • Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
• 12.7 US - Market size and forecast 2024-2029
  • Chart on US - Market size and forecast 2024-2029 ($ million)
  • Data Table on US - Market size and forecast 2024-2029 ($ million)
  • Chart on US - Year-over-year growth 2024-2029 (%)
  • Data Table on US - Year-over-year growth 2024-2029 (%)
• 12.8 UK - Market size and forecast 2024-2029
  • Chart on UK - Market size and forecast 2024-2029 ($ million)
  • Data Table on UK - Market size and forecast 2024-2029 ($ million)
  • Chart on UK - Year-over-year growth 2024-2029 (%)
  • Data Table on UK - Year-over-year growth 2024-2029 (%)
• 12.9 Germany - Market size and forecast 2024-2029
  • Chart on Germany - Market size and forecast 2024-2029 ($ million)
  • Data Table on Germany - Market size and forecast 2024-2029 ($ million)
  • Chart on Germany - Year-over-year growth 2024-2029 (%)
  • Data Table on Germany - Year-over-year growth 2024-2029 (%)
• 12.10 Canada - Market size and forecast 2024-2029
  • Chart on Canada - Market size and forecast 2024-2029 ($ million)
  • Data Table on Canada - Market size and forecast 2024-2029 ($ million)
  • Chart on Canada - Year-over-year growth 2024-2029 (%)
  • Data Table on Canada - Year-over-year growth 2024-2029 (%)
• 12.11 China - Market size and forecast 2024-2029
  • Chart on China - Market size and forecast 2024-2029 ($ million)
  • Data Table on China - Market size and forecast 2024-2029 ($ million)
  • Chart on China - Year-over-year growth 2024-2029 (%)
  • Data Table on China - Year-over-year growth 2024-2029 (%)
• 12.12 France - Market size and forecast 2024-2029
  • Chart on France - Market size and forecast 2024-2029 ($ million)
  • Data Table on France - Market size and forecast 2024-2029 ($ million)
  • Chart on France - Year-over-year growth 2024-2029 (%)
  • Data Table on France - Year-over-year growth 2024-2029 (%)
• 12.13 Italy - Market size and forecast 2024-2029
  • Chart on Italy - Market size and forecast 2024-2029 ($ million)
  • Data Table on Italy - Market size and forecast 2024-2029 ($ million)
  • Chart on Italy - Year-over-year growth 2024-2029 (%)
  • Data Table on Italy - Year-over-year growth 2024-2029 (%)
• 12.14 Spain - Market size and forecast 2024-2029
  • Chart on Spain - Market size and forecast 2024-2029 ($ million)
  • Data Table on Spain - Market size and forecast 2024-2029 ($ million)
  • Chart on Spain - Year-over-year growth 2024-2029 (%)
  • Data Table on Spain - Year-over-year growth 2024-2029 (%)
• 12.15 Japan - Market size and forecast 2024-2029
  • Chart on Japan - Market size and forecast 2024-2029 ($ million)
  • Data Table on Japan - Market size and forecast 2024-2029 ($ million)
  • Chart on Japan - Year-over-year growth 2024-2029 (%)
  • Data Table on Japan - Year-over-year growth 2024-2029 (%)
• 12.16 Mexico - Market size and forecast 2024-2029
  • Chart on Mexico - Market size and forecast 2024-2029 ($ million)
  • Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
  • Chart on Mexico - Year-over-year growth 2024-2029 (%)
  • Data Table on Mexico - Year-over-year growth 2024-2029 (%)
• 12.17 Market opportunity By Geographical Landscape
  • Market opportunity By Geographical Landscape ($ million)
  • Data Tables on Market opportunity By Geographical Landscape ($ million)

13 Drivers, Challenges, and Opportunity/Restraints

• 13.1 Market drivers
• 13.2 Market challenges
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities/restraints

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Product / Service
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • SWOT
• 15.5 Allarity Therapeutics Inc.
  • Allarity Therapeutics Inc. - Overview
  • Allarity Therapeutics Inc. - Product / Service
  • Allarity Therapeutics Inc. - Key offerings
  • SWOT
• 15.6 AstraZeneca Plc
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product / Service
  • AstraZeneca Plc - Key news
  • AstraZeneca Plc - Key offerings
  • SWOT
• 15.7 Bayer AG
  • Bayer AG - Overview
  • Bayer AG - Business segments
  • Bayer AG - Key news
  • Bayer AG - Key offerings
  • Bayer AG - Segment focus
  • SWOT
• 15.8 BeiGene Ltd.
  • BeiGene Ltd. - Overview
  • BeiGene Ltd. - Business segments
  • BeiGene Ltd. - Key offerings
  • BeiGene Ltd. - Segment focus
  • SWOT
• 15.9 Daiichi Sankyo Co. Ltd.
  • Daiichi Sankyo Co. Ltd. - Overview
  • Daiichi Sankyo Co. Ltd. - Product / Service
  • Daiichi Sankyo Co. Ltd. - Key offerings
  • SWOT
• 15.10 Everest Pharmaceuticals Ltd.
  • Everest Pharmaceuticals Ltd. - Overview
  • Everest Pharmaceuticals Ltd. - Product / Service
  • Everest Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.11 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 15.12 IMPACT Therapeutics
  • IMPACT Therapeutics - Overview
  • IMPACT Therapeutics - Product / Service
  • IMPACT Therapeutics - Key offerings
  • SWOT
• 15.13 Jeil Pharmaceuticals Co. Ltd.
  • Jeil Pharmaceuticals Co. Ltd. - Overview
  • Jeil Pharmaceuticals Co. Ltd. - Product / Service
  • Jeil Pharmaceuticals Co. Ltd. - Key offerings
  • SWOT
• 15.14 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
  • SWOT
• 15.15 Merck and Co. Inc.
  • Merck and Co. Inc. - Overview
  • Merck and Co. Inc. - Business segments
  • Merck and Co. Inc. - Key news
  • Merck and Co. Inc. - Key offerings
  • Merck and Co. Inc. - Segment focus
  • SWOT
• 15.16 Ono Pharmaceutical Co. Ltd.
  • Ono Pharmaceutical Co. Ltd. - Overview
  • Ono Pharmaceutical Co. Ltd. - Product / Service
  • Ono Pharmaceutical Co. Ltd. - Key offerings
  • SWOT
• 15.17 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Product / Service
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • SWOT
• 15.18 Zai Lab Ltd.
  • Zai Lab Ltd. - Overview
  • Zai Lab Ltd. - Product / Service
  • Zai Lab Ltd. - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations